The Securities and Exchange Commission has announced that it has resolved civil FCPA charges against the French drug company, Sanofi, and its Kazakh and Middle Eastern subsidiaries. The company will pay $25 million to settle allegations that it participated in bribery schemes to secure government tenders and increase prescriptions.
September 4, 2018
Pharmaceutical giant charged with bribery
Related by Topic
New Post
Federal prosecutors move to terminate Stericycle DPA in FCPA matter
April 28, 2025
News Alert
New Post
European Union issues first non-compliance fines under the Digital Markets Act
April 24, 2025
News Alert
New Post
DOJ to proceed with FCPA case involving bribes paid to Honduran officials
April 21, 2025
News Alert